Brokerages

[Brokerage Calls] Stocks to watch on October 1: Ultratech Cement, Muthoot Finance, Manappuram Finance, Amber, Syrma SGS, Sun Pharma and more

Stocks to watch today, Sep 30, 2025: Brokerages pick Coforge, Lupin, Kotak Bank, Astral, IndiGo; cautious on ONGC, Tata Motors, L&T

Prince Pipes share: Motilal Oswal maintains buy, sees 30% upside despite near-term demand weakness

Adani Green share: Jefferies maintains buy, sees 33% upside on capacity expansion and improving leverage

RBL Bank share: Morgan Stanley maintains underweight, sees 35% downside despite loan growth guidance

Bank of Baroda share: Morgan Stanley maintains underweight, sees 5.5% downside on margin pressure

SBI share: Morgan Stanley maintains equal-weight, sees 3.6% upside on steady loan growth and stable asset quality

JSW Energy share: Jefferies maintains buy, sees 30% upside on strong capacity addition outlook

JSW Energy share: Morgan Stanley maintains overweight, sees 23% upside as hydro acquisition expands portfolio

Adani Power share: Morgan Stanley initiates overweight, sees 29% upside on turnaround and growth outlook

Axis Bank share: Morgan Stanley maintains overweight, sees 17% upside on loan growth and deposit traction

Yes Bank, Vodafone Idea among stocks flagged with 15–25% downside potential by brokerages

Brokerage radar: Yes Bank may fall 19.3%, Vodafone Idea 25.6% from current levels

ICICI Bank, PNB Housing, Sun Pharma, D-Mart, Shriram Finance among top picks with 15–35% upside, say brokerages

Eternal share: Goldman Sachs maintains buy, sees 10% upside on Blinkit growth and margin expansion

Eternal stock: Goldman Sachs target at ₹360 implies 9.9% gain, Blinkit growth not yet priced in

Avenue Supermarts share: UBS maintains buy, sees 19% upside on accelerating growth and strong e-commerce play

DMart stock: UBS raises target to ₹5,600, sees 18.6% gain if revenue growth sustains above 20%

Sun Pharma share: Citi maintains buy, sees 35% upside on innovation revenue growth and global expansion

Sun Pharma stock: Citi target at ₹2,180 implies 34.6% gain, driven by Ilumya approval and US expansion